Chemotherapy is now established as an effective treatment for metastatic teratoma of the testis (Muggia, 1985; Peckham, 1985) . However following treatment a residual mass is common usually in the para-aortic nodes but also in the mediastinum or lungs. This may represent necrotic material or differentiated teratomatous elements. The concern is that there may be active tumour present or that differentiated elements may ultimately reactivate (Blandy, 1985) . Surgical excision of the residual mass is common practice and in most specialised centres retroperitoneal node dissection (RPND) is routinely performed post-chemotherapy. It has been reported that prognosis is related to the completeness of the excision (Tait et al., 1984) . Such surgery can be associated with considerable morbidity and occasional mortality (Donohoe & Rowland, 1981; Skinner et al., 1982) . Localised teratoma is however moderately radiosensitive (Peckham & Barrett 1981a ) -comparable with squamous carcinoma of the head and neck or transitional cell carcinoma of the urinary bladderand an alternative approach is to irradiate residual masses post-chemotherapy. This paper describes the use of radiotherapy post-chemotherapy in place of routine surgical excision in those patients with retroperitoneal lymphadenopathy at presentation. Emphasis has been placed on examining the incidence of local failure in the para-aortic area rather than the results of chemotherapy which have been described elsewhere (Wilkinson, 1985) .
Patients and methods
Between 1979 and 1982, 164 previously untreated patients with malignant teratoma of the testis or retroperitoneum were referred to this Institute for management. All patients had histological confirmation of malignancy either by orchidectomy, laparotomy or supraclavicular node biopsy and the material was reviewed in all instances. All patients had clinical examination, chest radiology, serum alpha-foetoprotein (AFP) and beta chorionic gonadotrophin (HCG) estimation and routine biochemical and haematological profiles. Computed tomography of the abdomen was performed in 145 patients, the remaining 19 being considered too ill at presentation for the examination. Seventy-seven patients had no evidence of retroperitoneal adenopathy at any time and are not considered further in this study. Computed tomography of the chest was performed if the chest radiograph was normal.
Stage one patients were entered into a surveillance study (Read et al., 1983) and all other stages received chemotherapy except for patients treated at the beginning of 1979 Who received radiotherapy as the primary treatment. Chemotherapy was given for two courses beyond marker remission or if there was no elevation of marker levels four courses were given for patients with small volume disease and six courses for bulky disease (Wilkinson, 1985) . Patients with retroperitoneal lymphadenopathy received radiotherapy one month after completion of chemotherapy when bone marrow function had recovered. Fields were directed to the para-aortic nodal area (and when involved the iliac nodes) using a parallel pair of opposed fields from a 4 or 8 MV linear accelerator. A central midplane dose of between 3,500 and 4,000 cGy was given in 16 or 20 fractions over 22 to 28 days (Gibb & Read, 1985 marker levels to normal. These patients were then considered for radiotherapy. In 21 patients there was progression of the para-aortic or other metastatic disease judged by persistent elevation of marker levels or radiological progression. In general these were patients with advanced large volume disease and all have subsequently progressed and died. There were two intercurrent and one treatment related deaths. Two patients did not have a reassessment of the para-aortic area after completion of treatment, one patient with paraaortic disease less than 5 cm at presentation is alive and disease-free, the other presented with advanced generalised disease including a palpable para-aortic mass. He was treated with chemotherapy followed by radiotherapy to a residual mediastinal mass but there was no re- (Table VI) . aRelapsed. Radiotherapy morbidity The morbidity of radiotherapy given as a primary treatment is well documented (Peckham et al., 1981b) . Only the 43 CR and RM patients receiving radiotherapy post-chemotherapy are considered here. The doses received are shown in Table VII .
No patient failed to complete the planned radiotherapy treatment. During radiotherapy mild nausea, abdominal colic and diarrhoea were common but no patient developed symptoms severe enough to warrant interruption of treatment. Some myelosuppression during radiotherapy occurred in all patients. Four patients had grade 1 leuocopenia (>2.0 and <3.0x 109 1-) and seven patients had grade 2 leucopenia (> 1.0 and <2.0 x 1091-1). Two patients had brief interruption of treatments but there were no infective episodes. Five patients had thrombocytopenia between 50 and 100 x 1091-1. Subcutaneous fibrosis in the irradiated area developing within six months of the conclusion of radiotherapy was observed in 6 patients, in 3 of whom it was sufficiently severe to produce some restriction of movement. Fibrosis occurred in 4/8 patients in whom the subcutaneous dose exceeded 4,290 cGy in 20 fractions in 28 days and 2/5 patients with a subcutaneous dose greater than 3,750 cGy in 16 fractions over 21 days. In six patients treated in the latter part of the present series and in patients treated subsequently 50% of the dose to the para-aortic area has been delivered using a rotation technique and no further cases of subcutaneous fibrosis have been observed following this modification which has also significantly reduced myelosuppression.
Discussion
The aim of this study was to assess the results of radiotherapy to the retroperitoneum following chemotherapy in metastatic teratoma of the testis. The relapse rate in the 'retroperitoneum was very low -only 2/60 attaining CR or leaving a residual mass -neither of whom had received radiotherapy to the retroperitoneum. Although this was not a randomised study there was no retroperitoneal relapse in the 47 patients receiving radiotherapy post-chemotherapy whereas 2/11 not receiving radiotherapy or an immediate laparotomy relapsed.
One further patient with a palpable para-aortic mass at presentation who did not have reassassment or radiotherapy of the para-aortic after chemotherapy subsequently relapsed in that area. Many centres advocate a retroperitoneal node dissection (RPND) for residual masses following chemotherapy. These operations are tedious and may involve resection and or repair of the aorta, inferior vena cava, bowel or ureter (Blandy, 1985) since the object of surgery is complete removal of the residual mass, not merely a biopsy (Rowland & Donohoe, 1984) . There may be considerable morbidity in the form of post-operative back pain and ejaculatory impotence. A complication rate of 25% and a mortality of 2-4% has been reported (Donohoe & Rowland, 1981; Skinner et al., 1982) . In patients receiving RPND following chemotherapy the incidence of active tumour his high. Rowland and Donohoe (1984) found tumour in 35% of patients following chemotherapy and Oliver et al. (1983) found that one third of cases had tumour. In a recent study (Vulgrin et al., 1985) of patients treated by chemotherapy and RPND malignant elements were found in 10/25 patients achieving complete remission. In a review of the experience of several centres Brenner et al. (1982) found residual malignant elements in 32% of patients. Only 7% of patients with necrosis, fibrosis or benign teratoma relapsed compared with 61% having residual malignancy. Although Tait et al. (1984) suggest that the ultimate prognosis may relate to the completeness or otherwise of the resection, patients with active tumour still require further chemotherapy as surgery is not curative in its own right.
In the present study 50/60 patients survived more than two years with only two para-aortic recurrences in patients not receiving radiotherapy. This suggests that radiotherapy is effective in sterilising minimal residual active tumour following chemotherapy. Previous experience of treating stage II patients by radiotherapy supports this since relapse within the irradiated area of the -abdomen was rare (Peckham et al., 1977) . The morbidity of a four week radical course of ratiotherapy is negligible in comparison with RPND (Peckham & Barrett, 1981b) and patients are spared further salvage chemotherapy. Although it may be argued that radiotherapy may compromise further chemotherapy the fields used in this study encompassed only the para-aortic area thereby keeping the volume of marrow irradiated to a minimum. This has been reduced further by delivering 50% of the tumour dose by a rotation technique rather than parallel opposed fields. This study also suggests that following radiotherapy residual masses may be safely observed since the majority will show a substantial reduction in size with the passage of time.
In conclusion this study suggests that the use of radiotherapy provides an alternative approach to the use of surgery post-chemotherapy in patients with para-aortic nodal disease. This approach spares patients the inconvenience and morbidity of a prolonged surgical procedure and the need for further chemotherapy should active tumour be found. Further studies are required to determine whether radiotherapy, is required in all patients or only those in whom there is a residual mass.
